- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03266055
Effects of Blueberry on Gut Microbiota and Metabolic Syndrome
October 2, 2023 updated by: Marie-Claude Vohl, Laval University
Prebiotic Effects of Blueberry in Overweight/Obese Individuals: Potential Role of the Gut Microbiota in Alleviating the Metabolic Syndrome.
There is growing evidence that nutritional intervention with dietary polyphenols can positively modulate the gut microbiota to improve cardiometabolic health.
Whether the beneficial effects of blueberries on obesity and the metabolic syndrome can be linked to their potential impact on the gut microbiota and intestinal integrity remains speculative at this time.
Moreover, the mechanisms of action underlying health benefits associated to blueberry consumption are still unknown.
The investigators are thus proposing to combine the study of metagenomics, transcriptomics and metabolomics to test whether a prebiotic activity of highbush blueberries can play a role in the prevention of obesity-linked metabolic syndrome in a clinical setting.
Study Overview
Status
Active, not recruiting
Conditions
Study Type
Interventional
Enrollment (Actual)
59
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Québec, Canada, G1V0A6
- Laval University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Men and premenopause women in good health
- Caucasians
- At least one of the following : BMI between 25 and 40 kg/m2 or Waist circumference ≥ 80 cm for women and ≥ 94 cm for men
- At least one of the following : TG ≥ 1.35 mmol/L or fasting insulinemia ≥ 42 pmol/L
Exclusion Criteria:
- Metabolic disorders (hypertension, diabetes, hypercholesterolemia)
- Regular use of medication affecting study parameters
- Use of natural health product in the last 3 months
- Use of antibiotics in the last 3 months
- Nicotine users
- Allergy or intolerance for blueberries
- Blueberry taste aversion
- More than 2 alcohol drinks par day
- Particular dietary habits (vegetarism, gluten-free diet, cetogenic diet...)
- Weight change of more than 5% in the last 3 months
- Surgery in the last 3 months or planed during the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Blueberry powder
|
Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.
|
Placebo Comparator: Blueberry placebo powder
|
Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in plasma insulin/glucose of overweight/obese men and women taking either blueberry powder or placebo blueberry powder
Time Frame: 12 months
|
12 months
|
Changes in plasma lipids/lipoproteins of overweight/obese men and women taking either blueberry powder or placebo blueberry powder
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in gene expression in overweight/obese men and women taking either blueberry powder or placebo blueberry powder
Time Frame: 3-6 months
|
3-6 months
|
Changes in metabolites concentration in overweight/obese men and women taking either blueberry powder or placebo blueberry powder
Time Frame: 3-6 months
|
3-6 months
|
Changes in the gut microbiota composition in overweight/obese men and women taking either blueberry powder or placebo blueberry powder
Time Frame: 3-6 months
|
3-6 months
|
Changes in blood pressure of overweight/obese men and women taking either blueberry powder or placebo blueberry powder
Time Frame: 12 months
|
12 months
|
Changes in intestinal integrity of overweight/obese men and women taking either blueberry powder or placebo blueberry powder
Time Frame: 12 months
|
12 months
|
Changes in inflammation biomarkers of overweight/obese men and women taking either blueberry powder or placebo blueberry powder
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Marie-Claude Vohl, Laval University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2017
Primary Completion (Actual)
January 14, 2019
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
July 6, 2017
First Submitted That Met QC Criteria
August 28, 2017
First Posted (Actual)
August 29, 2017
Study Record Updates
Last Update Posted (Actual)
October 3, 2023
Last Update Submitted That Met QC Criteria
October 2, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BLEUET 2017-135
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
Mayo ClinicCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on 50 g of blueberry powder, taken daily for 8 weeks
-
Laval UniversityActive, not recruitingMetabolic Syndrome | Gut MicrobiotaCanada
-
Hal ChapmanMassachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsRecruitingIdiopathic Pulmonary FibrosisUnited States
-
Evandro Chagas Institute of Clinical ResearchNot yet recruitingChronic Chagas DiseaseBrazil
-
University Hospital, RouenNot yet recruiting
-
Organon and CoCompleted
-
University of StellenboschUniversity of PittsburghUnknown
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedNeuroblastomaUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedNon-Hodgkin's Lymphoma | CNS Lymphoma | CNS Brain CancerUnited States